NEXAGON (lufepirsen ophthalmic gel): payments to doctors
Payments that named NEXAGON (lufepirsen ophthalmic gel) as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Glaukos Corporation?
Glaukos Corporation reported the most payments naming NEXAGON (lufepirsen ophthalmic gel). Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $42K
- Providers
- 1
- Transactions
- 6
- Average per transaction
- $7,035
The per-transaction average — $7,035 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1 providers the average total is $42,211, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Glaukos Corporation | $42,211 | 100.0% |
Other products from Glaukos Corporation
The company that reported the most payments naming NEXAGON (lufepirsen ophthalmic gel) also reports against these.
- iStent inject Trabecular Micro-Bypass Stent System$1,628,328
- iDose$1,404,659
- KXL System$1,350,637
- iStent Trabecular Micro-Bypass Stent System$1,282,585
- Travoprost Intraocular Implant - iDose$1,269,336
- iStent inject W$932,051
- iDoseTR$668,045
- Photrexa$610,061
- CE-marked KXLA system$576,090
- iAccess Precision Blade$409,253